Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 11:57 ET | Source: Spherix Global Insights

Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders

EXTON, PA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S....
October 31, 2025 10:37 ET | Source: Spherix Global Insights

Spherix Global Insights Launches Market Dynamix™: PD-1 Inhibition in Solid Tumors, Delivering a Comprehensive Assessment of Biosimilar and Subcutaneous PD-1 Market Dynamics Across Key Oncology Indications

EXTON, PA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth...
October 29, 2025 09:44 ET | Source: Spherix Global Insights

Targeted Biologics Expand in Early-Line gMG Treatment as New Entrants Prepare to Challenge Established Leaders

EXTON, PA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released its latest Patient Chart Dynamix™: Treatment Patterns in Generalized Myasthenia Gravis (US), delivering a...
October 28, 2025 09:24 ET | Source: Spherix Global Insights

Step Therapy Shifts and Pipeline Momentum Reshape the Membranous Nephropathy Treatment Landscape, according to Spherix Global Insights

EXTON, PA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of...
October 24, 2025 09:27 ET | Source: Spherix Global Insights

Evolving Treatment Landscape for Chronic Spontaneous Urticaria Highlights Significant Unmet Needs and Expanding Opportunities for Therapeutic Innovation

EXTON, PA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients...
October 22, 2025 11:57 ET | Source: Spherix Global Insights

Hemophilia Specialists Raise the Bar: Quality of Life and Innovation Drive Market Reordering

EXTON, PA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Hematologists across the United States are redefining what “success” looks like in hemophilia treatment, according to the latest findings from Market...
October 16, 2025 09:42 ET | Source: Spherix Global Insights

Sjögren’s Disease Remains an Underdiagnosed and Underguided Condition, Creating an Opening for Manufacturers to Shape the Future of Care, According to Spherix Global Insights

EXTON, PA, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Sjögren’s Disease (SjD) continues to present significant diagnostic and therapeutic challenges within rheumatology, according to Spherix Global Insights’...
October 15, 2025 10:12 ET | Source: Spherix Global Insights

Spherix Global Insights Expands Hematology Franchise to Include Oncology, Enhancing Advisory Services and Delivering Deeper Physician and Market Insights

EXTON, PA, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
October 14, 2025 11:14 ET | Source: Spherix Global Insights

Spherix Global Insights Identifies Emerging Trends in Market Access Across More Than Twenty Key Therapeutic Areas

EXTON, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights announces the release of Special Topix™: Payer Management Strategies, a comprehensive new analysis examining how U.S. health...
October 10, 2025 09:58 ET | Source: Spherix Global Insights

Priovant’s Brepocitinib Poised to Address Steroid-Sparing Gap in Dermatomyositis as Rheumatologists Anticipate 2026 Launch

EXTON, PA, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance...